About this event

  • Date and time Fri 11 Jun 2021 from 9:00am to 11 Jun 2021 at 6:30pm
  • Location Online
  • Organised by Radiology

Join us for this highly commended one-day online teaching course for a chance to delve into the entire patient journey from suspected prostate cancer to the advanced disease. This is also a chance to hear shortlisted candidates present their research for the Finzi Prize.

If you are attending the Finzi prize, the session will begin at 5:30pm and a separate Zoom link will be emailed to you to join the prize meeting. 

Using a framework of definable clinical states, you'll learn the value and uses of MRI and PET/CT imaging in prostate patients. The teachings will focus on how imaging can help advance clinical care rather than just imaging technologies. You'll also discover how next-generation imaging technologies can contribute to the personalisation of care.

During this session, you'll be able to:

  • Know in detail the pathological states, problems of categorisation, and clinical needs during the entire patient journey
  • Understand how imaging can help meet clinical priorities and so promote the personalisation of care in advancing clinical states
  • Show how next generation prostate imaging such as multiparametric MRI and MRI-directed biopsies, and whole-body MRI and PET/CT assessments with clinical biomarkers can create opportunities to support and manage pathways of patients

A CPD certificate with 6 CPD credits will be issued to those joining the webinar live as well as those who watch the recording afterwards. Certificates will be issued 7 days after the webinar to those who watch it live and after 30 days for those that watch the recording. Please note that the Finzi prize evening does not have CPD credits.

We would like to thank our sponsors Bayer, GE Medical System and Siemens Healthineers for their support of this webinar. Please note that the scientific programme and content has not been influenced in any way by the sponsors.

Join in the conversation online #RSMLive
Follow us on Twitter: @RoySocMed

Registration for this webinar will close 2 hours prior to the start time. You will receive the webinar link 2 hours before the meeting. Late registrations will not be accepted.

Webinar recordings will be available for registered delegates up to 30 days after the live webinar, via Zoom. The link will be sent 24 hours after the webinar takes place. 

This webinar will be recorded and stored by the Royal Society of Medicine and may be distributed in future on various internet channels.  

Key speakers

Professor Anwar Padhani

Consultant, Radiologist, Paul Strickland Scanner Centre, Mount Vernon Cancer Centre

Professor Giuseppe Petralia

Director, Unit of Precision imaging and Research, European Institute of Oncology, Milan, Italy

Professor Valeria Panebianco

Department of Radiological Sciences, Oncology and Pathology, Policlinico Umberto I, Sapienza University, Rome, Italy


Imaging and prostate cancer: Diagnosis, treatment and monitoring

Please note that bookings for the Imaging and prostate cancer meeting are separate from the Finzi prize meeting.

Welcome and introduction

Chair: Professor Anwar Padhani, Consultant, Radiologist, Paul Strickland Scanner Centre, Mount Vernon Cancer Centre

Session one: Prostate cancer diagnosis and staging

Detection with magnetic resonance imaging including scoring systems

Dr Heminder Kaur Sokhi, Consultant Radiologist, Paul Strickland Scanner Centre, Mount Vernon Hospital and The Hillingdon Hospitals NHS Foundation Trust

Magnetic resonance imaging directed biopsy strategies

Professor Jürgen Fütterer, Professor of Image-Guided Oncological Interventions, Radboud University/Radboud University Medical Center

Panel discussion - Disease detection
Comfort break
Impacts of magnetic resonance imaging directed pathway

Professor Anwar Padhani, Consultant, Radiologist, Paul Strickland Scanner Centre, Mount Vernon Cancer Centre 

Quality checkpoints in the MRI pathway

Dr Tristan Barrett, Department of Radiology, Addenbrooke’s Hospital and the University of Cambridge

Risk-based staging of known cancers and therapy decision making

Professor Giuseppe Petralia, Director, Unit of Precision imaging and Research, European Institute of Oncology, Milan, Italy

Panel discussion

Session two: Advancing disease

Advancing disease states

Chair: Professor Anwar Padhani 

Biochemical recurrence imaging detection

Professor Valeria Panebianco, Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Rome, Italy

Image directed salvage treatments

Dr Alison Tree, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust

Panel discussion – recurrence and oligometastatic treatments
Tea and coffee break
Advanced prostate cancer – therapy choices

Dr Aurelius Omlin, Medical Oncologist, GU Oncology Team Lead, Cantonal Hospital of St.Gallen, Switzerland

Advanced prostate cancer – imaging therapy monitoring

Dr Nina Tunariu, Consultant Radiologist, The Royal Marsden NHS Foundation Trust

Panel discussion and concluding remarks
Close of meeting
Finzi prize meeting

Welcome and introduction
Reversing the trend of Friday peak for metastatic spinal cord compression referrals

Dr Olusola (Sola) Adeleke

Contrast enhanced ultrasound of testicular tumours: Quantitative analysis of enhancement characteristics

Dr Andrew Nanapragasam

18F-Fluorocholine PET/CT in persistent/recurrent primary hyperparathyroidism

Dr Mitesh Naik

Impact in reducing lens radiation in CT Brain through technician education in a busy Scottish general teaching hospital

Dr Paul Donnelly

Awarding of Finzi prize
End of prize meeting




Disclaimer: All views expressed in this webinar are of the speakers themselves and not of the RSM nor the speaker's organisations. 

Special rates for difficult times 

The RSM wishes to offer healthcare professionals continued learning opportunities during the coronavirus pandemic. The RSM’s weekly COVID-19 Series webinars remain free of charge, while there will be small charges to register for other online education. These fees will enable the RSM to continue its programme of activities and will apply during the course of the pandemic.